Abstract
ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Current Bioactive Compounds
Title: AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Volume: 7 Issue: 1
Author(s): David P. Nowotnik
Affiliation:
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Abstract: ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Export Options
About this article
Cite this article as:
P. Nowotnik David, AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163794
DOI https://dx.doi.org/10.2174/157340711795163794 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Management of Advanced Staged Ovarian Cancer in a National Cancer Center: Comparison of the Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
Current Women`s Health Reviews Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology miR-666-3p Mediates the Protective Effects of Mesenchymal Stem Cell-derived Exosomes Against Oxygen-glucose Deprivation and Reoxygenation- induced Cell Injury in Brain Microvascular Endothelial Cells via Mitogen-activated Protein Kinase Pathway
Current Neurovascular Research Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Current Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
Current Cancer Drug Targets The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Current Drug Delivery Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy
Recent Patents on Nanomedicine Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry